Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina

Core Insights - Cardiac Biotech Solutions, Inc. has entered into a five-year exclusive distribution agreement with Noventis Medical for its non-invasive cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina [1][2][3] - The contract value for the distribution rights is set at $600,000 USD, with Noventis Medical also granted a right of first refusal for future distribution opportunities in other Central and South American countries [2][3] Company Developments - The CEO of Cardiac Biotech Solutions expressed enthusiasm about expanding international presence and strengthening market reach in Latin America through this partnership [3] - Noventis Medical aims to provide reliable solutions for heart issue identification in the Latin American market, addressing the high prevalence of cardiovascular disease in the region [3] - The company continues to advance the global commercialization of its MyCardia AT event monitoring platform, which features lightweight wearable technology and cloud-based connectivity [3][5] Product Information - MyCardia AT integrates mobile applications for iOS, Android, and WeChat, enhancing patient compliance and providing accurate information for physicians [5] - The company has secured regulatory clearance in the U.S. and is progressing with submissions in Canada and China, marking significant milestones in its mission to deliver advanced cardiac monitoring solutions [3]